Pulmonx Corp

NASDAQ:LUNGUnited States

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solutions include Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), which is designed to treat severe emphysema patients. Its solutions provide bronchoscopic lung volume reduction without surgery. Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape. The StratX Platform is used to identify patients eligible for treatment with Zephyr Valves. It operates in North America, Europe and Asia Pacific.

Contact Information

Headquarters

700 Chesapeake DrREDWOOD CITY, CA, United States 94063

Phone

650-934-2600

Fax

302-655-5049

Executives

Independent Chairman of Board

Dana Mead

President, Chief Executive Officer, Director

Glendon French

Chief Financial Officer

Derrick Sung

General Counsel

David Lehman

Chief Commercial Officer

Geoffrey Rose